University of Oulu

Almahmoudi, R., Salem, A., Murshid, S., Dourado, M. R., Apu, E. H., Salo, T., & Al-Samadi, A. (2019). Interleukin-17F Has Anti-Tumor Effects in Oral Tongue Cancer. Cancers, 11(5), 650. https://doi.org/10.3390/cancers11050650

Interleukin-17F has anti-tumor effects in oral tongue cancer

Saved in:
Author: Almahmoudi, Rabeia1,2; Salem, Abdelhakim1,2; Murshid, Sakhr1;
Organizations: 1Department of Oral and Maxillofacial Diseases, University of Helsinki, Biomedicum Helsinki 1, 00014 Helsinki, Finland
2Translational Immunology Research Program (TRIMM), University of Helsinki, Biomedicum Helsinki 1, 00014 Helsinki, Finland
3Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Campinas-SP, Piracicaba, São Paulo 13083-970, Brazil
4Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA
5Department of Diagnostics and Oral Medicine, Research Group of Cancer Research and Translational Medicine, Medical Faculty, University of Oulu, 90014 Oulu, Finland
6 Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA
7Medical Research Centre, Oulu University Hospital, 90220 Oulu, Finland
8Cancer and Translational Medicine Research Unit, University of Oulu, 90014 Oulu, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 2.1 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2019061220079
Language: English
Published: Multidisciplinary Digital Publishing Institute, 2019
Publish Date: 2019-06-12
Description:

Abstract

We recently showed that extracellular interleukin-17F (IL-17F) correlates with better disease-specific survival in oral tongue squamous cell carcinoma (OTSCC) patients. However, the underlying mechanisms of such effect remain obscure. Here, we used qRT-PCR to assess the expression of IL-17F and its receptors (IL-17RA and IL-17RC) in two OTSCC cell lines (HSC-3 and SCC-25) and in normal human oral keratinocytes (HOKs). IL-17F effects on cancer cell proliferation, migration, and invasion were studied using a live-imaging IncuCyte system, and a Caspase-3/7 reagent was used for testing apoptosis. 3D tumor spheroids were utilized to assess the impact of IL-17F on invasion with or without cancer-associated fibroblasts (CAFs). Tube-formation assays were used to examine the effects of IL-17F on angiogenesis using human umbilical vein endothelial cells (HUVEC). OTSCC cells express low levels of IL-17F, IL-17RA, and IL-17RC mRNA compared with HOKs. IL-17F inhibited cell proliferation and random migration of highly invasive HSC-3 cells. CAFs promoted OTSCC invasion in tumor spheroids, whereas IL-17F eliminated such effect. IL-17F suppressed HUVEC tube formation in a dose-dependent manner. Collectively, we suggest that IL-17F counteracts the pro-tumorigenic activity in OTSCC. Due to its downregulation in tumor cells and inhibitory activity in in vitro cancer models, targeting IL-17F or its regulatory pathways could lead to promising immunotherapeutic strategies against OTSCC.

see all

Series: Cancers
ISSN: 2072-6694
ISSN-E: 2072-6694
ISSN-L: 2072-6694
Volume: 11
Issue: 5
Article number: 650
DOI: 10.3390/cancers11050650
OADOI: https://oadoi.org/10.3390/cancers11050650
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Subjects:
Funding: This research was funded by Sigrid Jusélius Foundation, Cancer Society of Finland (Syöpäjärjestöt), Oulu University Hospital MRC grant, Emil Aaltonen Foundation (Emil Aaltosen säätiö), Finnish Dental Society (Apollonia), Orion Research Foundation grant, and Helsinki University Central Hospital Research Funds.
Copyright information: © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
  https://creativecommons.org/licenses/by/4.0/